Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON53530Not yet recruiting
Open-label trial of radiprodil in GRIN-related disorder (3 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Adverse events, serious adverse events, and adverse drug reactions, Vital signs and 7 more. Planned start Feb 2023; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON53530.